Clinical Trials

58 enrolled

Astrocytoma, Glioblastoma, Glioma

NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

6,452 enrolled 1 FDA

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04940052 2026-05-22

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Phase 3 Active not recruiting

153 enrolled 15 charts

Differentiated Thyroid Cancer (DTC)

NCT04439292 2026-05-19

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

44 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT01989585 2026-05-13

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

75 enrolled

Melanoma

NCT02196181 2026-05-13

Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread

280 enrolled

Melanoma

NCT04439279 2026-05-07

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

35 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT02642042 2026-05-01

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

60 enrolled 24 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02079740 2026-04-29

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

96 enrolled 30 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT03363217 2026-04-24

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

114 enrolled

Brain Neoplasms, Glioma, Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03149029 2026-04-21

Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma

16 enrolled 10 charts

Melanoma

NCT05358249 2026-04-14

KontRASt-03

74 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT01979523 2026-04-13

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

42 enrolled 13 charts

Uveal Melanoma

NCT02015117 2026-04-13

Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases

10 enrolled

Brain Neoplasms

NCT02152995 2026-04-13

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

34 enrolled 18 charts

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT04439318 2026-04-13

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

50 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439357 2026-04-13

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

4 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04557956 2026-04-02

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

16 enrolled

Melanoma

NCT03091257 2026-03-13

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

30 enrolled

Plasma cell

Multiple Myeloma

NCT04417621 2026-03-12

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

134 enrolled

Melanoma

NCT05907304 2026-02-27

SEACRAFT-1

DermatologicGastrointestinalHead & NeckThoracic

86 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms

NCT06346067 2026-02-27

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Phase 3 Active not recruiting

78 enrolled

Melanoma

NCT04666272 2026-02-19

Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection

Active not recruiting

78 enrolled

Melanoma

NCT04675710 2026-02-19

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

30 enrolled

Phase 3 Active not recruiting

Thyroid Carcinoma, Anaplastic

NCT02224781 2026-02-18

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

267 enrolled 8 charts

Melanoma

NCT02231775 2026-02-13

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

58 enrolled

Melanoma

NCT04201457 2026-02-03

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

57 enrolled

Glioma

NCT03225664 2026-01-16

Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

37 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

105 enrolled

Thoracic

EGFR-mutant Non-small Cell Lung Cancer

NCT03065387 2026-01-12

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

93 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03087071 2026-01-12

Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer

59 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04111458 2026-01-12

A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

71 enrolled

Other solid neoplasm

Solid Tumors, KRAS Mutation; SOS1

NCT02910700 2025-12-17

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

52 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT01972347 2025-12-16

Neo Combi

35 enrolled

Fever, Melanoma

NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Other solid neoplasmSarcoma

610 enrolled

Advanced Solid Tumors

NCT04544111 2025-10-07

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

19 enrolled

Thyroid cancer, Hurthle cell, Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenoma, Oxyphilic, Adenocarcinoma, Follicular

NCT01990196 2025-08-17

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

Phase EARLY_PHASE1 Active not recruiting

45 enrolled

Genitourinary

Prostatic Neoplasms

NCT03085056 2025-07-03

Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

13 enrolled

Thyroid Carcinoma, Anaplastic

NCT04238624 2025-07-02

Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

16 enrolled

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT02881242 2023-05-01

Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer